Hypoxia-inducible factor 2α: a novel target in gliomas-Reference-Cited by-同舟云学术

Hypoxia-inducible factor 2α: a novel target in gliomas

Published:2018-09-01 Issue:18 Volume:10 Page:2227-2236
ISSN:1756-8919
Container-title:Future Medicinal Chemistry
language:en
Short-container-title:Future Medicinal Chemistry

Author:

Renfrow Jaclyn J¹²,Soike Michael H³,Debinski Waldemar⁴²,Ramkissoon Shakti H⁵⁶,Mott Ryan T⁵²,Frenkel Mark B¹,Sarkaria Jann N⁷,Lesser Glenn J²⁸,Strowd Roy E²⁸⁹

Affiliation:

1. Department of Neurological Surgery, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA

2. Brain Tumor Center of Excellence, Wake Forest Comprehensive Cancer Center, Winston-Salem, NC 27157, USA

3. Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA

4. Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA

5. Department of Pathology, Wake Forest Baptist Medical Center, Winston-Salem, NC27157, USA

6. Foundation Medicine, Inc., Morrisville, NC 27560, USA

7. Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA

8. Department of Internal Medicine, Section on Hematology & Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA

9. Department of Neurology, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA

Abstract

Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/fmc-2018-0163

Reference85 articles.

1. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects

2. Hypoxia-induced dedifferentiation of tumor cells – A mechanism behind heterogeneity and aggressiveness of solid tumors

3. Hypoxia — a key regulatory factor in tumour growth

4. Glioma Stem Cell Maintenance: The Role of the Microenvironment

5. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma;Molecular Brain;2024-07-02

2. Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review;Cancers;2024-05-30

3. Evaluation of the effects of simulated hypoxia by CoCl2 on radioresistance and change of hypoxia-inducible factors in human glioblastoma U87 tumor cell line;Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis;2024-01

4. The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia;EMBO Molecular Medicine;2023-10-09

5. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma;Journal of Neuro-Oncology;2023-10